Neuraxis(NRXS.US)

Company Encyclopedia
View More
name
Neuraxis
NRXS.US
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc.
1.378 T
NRXS.USMarket value -Rank by Market Cap -/-

Financial Score

02/01/2026 Update
C
Health Care EquipmentIndustry
Industry Ranking91/175
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-3433.12%E
    • Profit Margin-224.24%E
    • Gross Margin83.30%A
  • Growth ScoreA
    • Revenue YoY36.89%A
    • Net Profit YoY1.24%C
    • Total Assets YoY405.25%A
    • Net Assets YoY227.37%A
  • Cash ScoreB
    • Cash Flow Margin-40.38%D
    • OCF YoY36.89%A
  • Operating ScoreA
    • Turnover0.97A
  • Debt ScoreD
    • Gearing Ratio60.44%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Abeona Therapeutics CEO Vishwas Seshadri Reports Sale of Common Shares

    Vishwas Seshadri, CEO of Abeona Therapeutics Inc., has reported the sale of common shares of the company. The full filing is available through the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. The original content was published via EDGAR by Abeona Therapeutics Inc.

    Reuters·
    US
    ABEO
    +1.74%
    Reuters·
    US
    ABEO
    +1.74%

    Neuraxis shares are trading higher after Craig-Hallum maintained the stock with a Buy rating and raised the price target from $7 to $8.

    benzinga_article·
    US
    NRXS
    +0.67%
    benzinga_article·
    US
    NRXS
    +0.67%

    NeurAxis shares are trading higher after the company announced new medical policy coverage from a national health insurer for Percutaneous Electrical Nerve Field Stimulation.

    benzinga_article·
    US
    NRXS
    +0.67%
    benzinga_article·
    US
    NRXS
    +0.67%

    NeurAxis Secures VA Federal Supply Schedule Contract for IB-Stim

    NeurAxis Inc. has secured a VA Federal Supply Schedule contract for its IB-Stim® product, effective December 1, 2025. This contract positions NeurAxis as a federal contractor, facilitating entry into the VA health system. The company anticipates that this award will bolster commercial momentum alongside expanding reimbursement and clinical adoption.

    Reuters·
    US
    NRXS
    +0.67%
    Reuters·
    US
    NRXS
    +0.67%

    NeurAxis, Inc. Reports Increased Sales Amidst Ongoing Losses

    NeurAxis, Inc. (NRXS) reported Q3 earnings with net sales increasing to $811,414 from $666,625 year-over-year. However, the company faced a net loss of $2,122,796 due to high operational costs. Key metrics showed an operating loss of $2,100,085, despite an improved cash position of $4,377,109 from financing activities. NeurAxis aims to expand its market presence and secure insurance coverage for its products to enhance future revenue growth and financial stability.

    Tip Ranks·
    US
    NRXS
    +0.67%
    Tip Ranks·
    US
    NRXS
    +0.67%
    © 2026 Longbridge｜Disclaimer